NASDAQ:MBRX Moleculin Biotech Q3 2026 Earnings Results & Report $7.87 -0.19 (-2.36%) Closing price 11/13/2026 03:59 PM EasternExtended Trading$7.82 -0.05 (-0.70%) As of 11/13/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Moleculin Biotech missed analyst earnings expectations in its Q3 2026 results, released November 13, 2026. The company reported EPS of -$9.59 versus the -$8.87 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2026Report DateNovember 13, 2026TimeAfter Market ClosesConference Call7:00 AM ET Moleculin Biotech EPS ResultsActual EPS-$9.59Consensus EPS -$8.87Beat/MissMissed by -$0.72One Year Ago EPSN/AEPS Beat Rate2 of last 4 quartersMoleculin Biotech Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesQuarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsQuarterly report(10-Q) Moleculin Biotech Q3 2026 Earnings FAQ Did Moleculin Biotech beat earnings estimates for Q3 2026? Moleculin Biotech (NASDAQ:MBRX) reported earnings of -$9.59 per share for Q3 2026, missing the consensus estimate of -$8.87. The report was announced on Friday, November 13, 2026. Moleculin Biotech Earnings HeadlinesMoleculin Secures Australian Patent for Annamycin Formulation TechnologyNovember 12 at 8:37 AM | globenewswire.comPreclinical Data Show Annamycin Makes Pancreatic Cancer Responsive to Checkpoint Inhibitors, Opening a Combination Path with ImmunotherapiesNovember 10, 2026 | globenewswire.comWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indicator for a single $7 payment. Others previously paid $500. The indicator flashes a Crash Alert as a cue to exit or go short, and a Bull Run Alert as a cue to buy or go long. No strings attached, and Wood says there is an unusual reason behind the steep discount.November 14 at 1:00 AM | Base Camp Trading (Ad)Moleculin Biotech (NASDAQ:MBRX) Stock Gets Downgrade from Wall Street ZenNovember 7, 2026 | americanbankingnews.comMoleculin Biotech (MBRX) Projected to Post Earnings on ThursdayNovember 5, 2026 | americanbankingnews.comMoleculin Announces Acceptance of Annamycin Data for Presentation at the 2026 American Society of Hematology (ASH) Annual MeetingNovember 4, 2026 | globenewswire.comSee More Moleculin Biotech Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Moleculin Biotech? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Moleculin Biotech and other key companies, straight to your email. Email Address About Moleculin BiotechMoleculin Biotech (NASDAQ:MBRX) is a clinical-stage pharmaceutical company focused on developing treatments for cancers and other serious diseases. The company uses its proprietary technology platforms to design drug candidates intended to address treatment resistance, improve drug delivery, and target biological pathways involved in disease progression. Moleculin’s lead program is Annamycin, a liposomal formulation of the anthracycline doxorubicin being investigated for acute myeloid leukemia and soft-tissue sarcoma. The company has also developed investigational compounds including WP1066, an immunotherapy candidate designed to inhibit STAT3 and related signaling pathways, and WP1122, which is intended to interfere with cancer-cell glucose metabolism. These programs remain in clinical or preclinical development and are not approved for general commercial use. Headquartered in Houston, Texas, Moleculin conducts research and clinical-development activities in the United States and has pursued clinical programs in Europe. The company is led by Walter Klemp, who serves as chairman and chief executive officer. Moleculin Biotech trades on the Nasdaq Capital Market under the symbol MBRX.View Moleculin Biotech ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles 3 Building-Materials Stocks Rallying While Homebuilders Struggle to Find BuyersMarketBeat Week in Review – 11/9 - 11/13Nu Holdings Earnings Show a Compounder Priced Like a Brazil BetCerebras Q3 Results: How Much More Proof Does Wall Street Need?YETI Beat on Earnings, But Its Sales Tell a Different StoryCostco's Record $30 Dividend Shows Just How Strong Its Cash Machine IsLightPath Technologies' Record Backlog Highlights a Bigger Defense Opportunity Upcoming Earnings Home Depot (11/17/2026)Walt Disney (11/17/2026)NVIDIA (11/17/2026)Lowe's Companies (11/18/2026)TJX Companies (11/18/2026)Target (11/18/2026)Palo Alto Networks (11/18/2026)NetEase (11/19/2026)Alibaba Group (11/19/2026)PDD (11/19/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
